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Background. Fetuin-A is a glycoprotein produced in the liver and related to metabolic syndrome; fetuin-A secretion is divergently
regulated in different pathological conditions. In girls with polycystic ovary syndrome (PCOS), insulin sensitization results in a
more favorable endocrine-metabolic outcome than oral contraception; we assessed whether those differences are underscored by
changes in circulating fetuin-A. Methods. Fetuin-A concentration endocrine-metabolic markers and hepatovisceral fat were
measured longitudinally in 35 PCOS girls [age, 16 yr; body mass index (BMI), 23 kg/m2] randomized to receive either oral
contraception [ethinylestradiol-levonorgestrel (n = 18)] or a low-dose combination of spironolactone, pioglitazone, and
metformin (SPIOMET, n = 17) over 12 months. Healthy adolescent girls (age- and BMI-matched) were used as controls (n = 25).
Results. Pretreatment fetuin-A serum levels in PCOS girls were lower than those in controls. After 12 months on treatment, fetuin-
A raised to control levels only in the SPIOMET subgroup (P = 0 009, versus oral contraception); this increase was paralleled by a
healthier metabolic profile with less hepatic fat (by MRI); baseline serum fetuin-A as well as the changes over 12 months was
inversely related to hepatic adiposity. Conclusions. A low-dose combination of insulin sensitizers and an antiandrogen—but not
oral contraception—normalizes fetuin-A levels in adolescent girls with PCOS. This trial is registered with ISRCTN29234515.
1. Introduction
Fetuin-A (α2-HS glycoprotein, AHSG) is a glycoprotein
produced primarily in the liver and secreted into circula-
tion in high concentrations in humans with fatty liver dis-
ease [1]; it binds the insulin receptor and inhibits hepatic
and muscle insulin signaling resulting in insulin resistance
[2]. In humans, high levels of fetuin-A have been associ-
ated with greater risks for type 2 diabetes (T2D) and with fea-
tures of the metabolic syndrome [3]; paradoxically, increased
fetuin-A concentrations prevent vascular calcification and
exert a protective role in systemic inflammation, suggesting
that fetuin-A secretion can be divergently regulated in differ-
ent pathological conditions [4].
Polycystic ovary syndrome (PCOS) is the most common
cause of hirsutism, acne, and menstrual irregularity in girls
and young women and associates to comorbidities in
adulthood, including subfertility and T2D. We have previ-
ously shown that in adolescent girls with PCOS, oral contra-
ception (OC)—as compared to combined low-dose insulin
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sensitization plus antiandrogen therapy—is linked to a less
favorable endocrine-metabolic profile [5, 6]. To date, the
available studies reporting fetuin-A in PCOS have been per-
formed in adult women, include heterogeneous populations,
and have a cross-sectional nature [7–9]. Here, we assessed
longitudinally whether the divergent effects of oral contra-
ception and low-dose combined insulin sensitization plus
antiandrogen therapy in adolescent PCOS are underscored
by changes in circulating fetuin-A.
2. Subjects and Methods
2.1. Study Population and Design. The study population con-
sisted of 35 nonobese adolescent girls with PCOS [mean age,
16 yr; body mass index (BMI), 23 kg/m2]; all of them were at
least 2 yr beyond menarche. The inclusion criteria were as
described [10] (1) hirsutism (score> 8 on Ferriman and
Gallwey scale); (2) oligomenorrhea (menstrual intervals> 45
days); and (3) absence of sexual activity throughout the study
duration (and thus, no need for contraception). The girls
were recruited in the Adolescent Endocrinology Unit of Sant
Joan de Déu University Hospital, Barcelona, Spain [10].
Recruitment was biased against overweight/obesity because,
in our setting, those girls are primarily referred to the ado-
lescent obesity unit. Exclusion criteria were thyroid dys-
function, anemia, bleeding disorder, hyperprolactinemia,
Cushing syndrome, adrenal hyperplasia, liver or kidney dys-
function, and use of drugs affecting gonadal or renal function
or carbohydrate or lipid metabolism. Patients were included
in a randomized, open-label study comparing the effects of
OC with ethinylestradiol-levonorgestrel [EE-LNG; 20μg of
EE plus 100mg of LNG for 21 of 28 days, placebo for 7 of
28 days; Loette Diario, Pfizer, Madrid, Spain] with those of
a low-dose combination of spironolactone 50mg/d, pioglita-
zone 7.5mg/d, and metformin 850mg/d (SPIOMET). The
study was registered as ISRCTN29234515 and lasted for 24
months (12 months on treatment; then 12 months off treat-
ment) [10]. The present report specifically included those
girls with complete longitudinal data in whom the remaining
serum sample was sufficiently abundant to measure fetuin-A
at baseline and after 12 months on treatment (~90% of the
initial study population, n = 18 and n = 17 in the EE-LNG
and SPIOMET subgroups, resp.). Twenty-five age- and
BMI-matched healthy girls recruited in nearby schools
served as controls. All had regular menstrual cycles, and none
was hirsute or was on OC or other medications affecting
ovarian function or carbohydrate or lipid metabolism.
2.2. Clinical and Endocrine-Metabolic Assessments.One inves-
tigator (unblinded to treatment) measured weight and height
(Harpenden Stadiometer) and scored hirsutism (Ferriman-
Gallwey). Systolic and diastolic blood pressures were recorded
after a 5-minute rest with the girl supine, using an electronic
sphygmomanometer (767 series, Welch Allyn, Spain).
Endocrine-metabolic assessments were performed in
the early morning, in the follicular phase (days 3–7) of the
cycle or after 2 months of amenorrhea, as described [5].
Briefly, circulating insulin and SHBG were assayed by
immunochemiluminescence (IMMULITE 2000, Diagnostic
Products, Los Angeles, CA). HOMA-insulin resistance
(HOMA-IR) was calculated as fasting insulin inmU/L ×
fasting glucose inmg/dL /405. Serum C-reactive protein
(CRP) was analyzed by immunochemiluminescence
(ARCHITECT i2000SR, Abbott Diagnostics, Abbot Park,
IL, USA); intra- and interassay coefficients of variation
(CVs)were<10%.HMWadiponectinwas assessedbyELISA
(R&D Systems, Minneapolis, MN, USA); intra- and interas-
say CVs were <9%. Circulating fetuin-A was assessed with a
specific ELISA (fetuin-A, R&D systems, Minneapolis,
MN, USA); the intra- and interassay CVs were 4.2%
and 7.4%, respectively.
2.3. Abdominal Fat Partitioning. Subcutaneous, visceral, and
hepatic fatwas assessedbymagnetic resonance imaging (MRI)
using a multiple-slice MRI 1.5 Tesla scan (Signa LX Echo
Speed Plus Excite, General Electric, Milwaukee, WI) [10].
2.4. Statistical Analyses and Ethics. Statistical analyses were
performed with SPSS 23.0 (SPSS Inc. Chicago, IL). Results
are expressed as mean± SEM. Comparisons within and
between groups at each time point were performed using
general linear model. Correlation analysis was used to study
the associations between fetuin-A levels and auxological
and endocrine-metabolic parameters. Two-way analysis of
variance (ANOVA) was performed to assess the influence
of treatment and time on fetuin-A levels. P < 0 05 was con-
sidered statistically significant.
The study was conducted after approval by the Institu-
tional Review Board of Sant Joan de Déu University Hospital,
after written consent by parents and after assent by each of
the participants, including the healthy controls who allowed
to obtain indicative values.
3. Results
Both treatments reduced androgen excess comparably, but
SPIOMET was followed by a more favorable endocrine-
metabolic profile, as expected (see Table 1 for differences in
selected variables between subgroups).
Pretreatment serum concentrations of fetuin-A in PCOS
girls were lower than those in controls. After 12 months on
treatment, fetuin-A levels increased only in the SPIOMET
subgroup (P = 0 009 versus the OC subgroup), reaching con-
trol levels (Figure 1, Table 1).
At baseline, circulating fetuin-A correlatednegativelywith
hepatic fat in both controls and PCOS girls (r = −0 739;
P = 0 03 and r = −0 446; P = 0 006, resp.). After treatment,
fetuin-A negatively associated with visceral fat in the
SPIOMETsubgroup (r = −0 583,P = 0 004) andwithdiastolic
blood pressure in both the SPIOMET and OC subgroups
(r = −0 729, P = 0 002, and r = −0 584, P = 0 03, resp.).
The change in serum fetuin-A concentrations 0–12
months correlated negatively with diastolic blood pressure
(r = −0 442; P = 0 039), hepatic fat (r = −0 647; P = 0 002),
and C-reactive protein (CRP; r = −0 − 617; P = 0 003),
only in the SPIOMET subgroup. Two-way ANOVA showed
that both time and treatment have an effect on fetuin-A levels
(P = 0 02 and P = 0 006, resp.).
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Table 1: Data from adolescent girls with polycystic ovary syndrome (PCOS) who were randomized to receive either ethinylestradiol-
levonorgestrel (EE-LNG; n = 18) or low-dose spironolactone-pioglitazone-metformin (SPIOMET; n = 17) for 12 months.
Controls (n = 25)
All PCOS (n = 35) EE-LNG (n = 18) SPIOMET (n = 17)






Age (year) 15.6± 0.2 15.8± 0.2 15.9± 0.3 — — 15.7± 0.3 — —
BMI (kg/m2) 22.2± 0.5 23.6± 0.5 23.9± 0.8 24.0± 0.8 0.04± 0.27 23.1± 0.7 23.0± 0.7 −0.31± 0.20
SBP (mmHg) 112± 2 114± 1 115± 2 112± 3 −3.2± 2.9 113± 2 109± 1b −4.9± 2.2
DBP (mmHg) 70± 1 71± 1 72± 2 75± 2 3.7± 2.9 70± 1 70± 1 −0.5± 1.6
AST (UI/L) 17.8± 0.7 16.0± 0.5 15.7± 0.7 16.5± 1.1 0.8± 0.7 16.3± 0.9 17.3± 1.0 0.8± 0.9
ALT (UI/L) 15.0± 1.1 14.2± 0.8 15.1± 1.3 18.9± 2.3b 3.9± 1.7 13.2± 0.6 15.4± 1.5 1.7± 1.2
GGT (UI/L) 13.9± 1.4 12.3± 0.4 12.3± 0.7 16.4± 1.0d,i 4.1± 0.9 12.2± 0.6 10.9± 0.4 −1.1± 0.6g
CRP (nmol/L) 7.5± 1.5 15.3± 2.3∗∗ 14.5± 2.3 28.5± 5.9b,i 14± 6.6 16.1± 4.2 5.5± 0.8c −10.6± 3.7f
N/L ratio 1.6± 0.1 1.8± 0.1 1.9± 0.2 1.8± 0.3 −0.1± 0.4 1.8± 0.1 1.6± 0.2 −0.2± 0.1
Glucose (mmol/L) 5.1± 0.1 4.7± 0.1∗∗∗ 4.7± 0.1 4.5± 0.1b −0.2± 0.1 4.6± 0.1 4.3± 0.1c −0.3± 0.1
Insulin (pmol/L) 56± 6 80± 7∗ 92± 12 110± 18h 18± 13 70± 7 44± 7c −27± 7g
HOMA-IR 1.9± 0.2 2.3± 0.1 2.5± 0.2 2.5± 0.3i 0.2± 0.4 2.1± 0.2 1.2± 0.2c −0.8± 0.2e
HDL-C (mmol/L) 1.44± 0.04 1.31± 0.04∗ 1.34± 0.05 1.35± 0.06 0.02± 0.05 1.28± 0.05 1.40± 0.07 0.12± 0.06
LDL-C (mmol/L) 2.26± 0.11 2.31± 0.09 2.31± 0.13 2.62± 0.19 0.31± 0.15 2.30± 0.12 2.32± 0.10 0.01± 0.07
Triglycerides (mmol/L) 0.63± 0.05 0.63± 0.04 0.60± 0.06 0.62± 0.04 0.02± 0.05 0.66± 0.07 0.56± 0.05 −0.10± 0.05
Testosterone (nmol/L) 0.97± 0.05 2.01± 0.10∗∗∗ 2.14± 0.19 0.09± 0.08d −1.23± 0.17 1.89± 0.08 0.96± 0.08d −0.93± 0.09
SHBG (nmol/L) 58± 4 29± 2∗∗∗ 30± 3 63± 7d,i 33± 6 28± 2 32± 3 3± 3g
Fetuin-A (g/L) 1.18± 0.05 0.92± 0.03∗∗∗ 0.93± 0.04 0.94± 0.04h 0.01± 0.07 0.92± 0.05 1.13± 0.05c 0.23± 0.07e
Subcutaneus fat (cm2)† 98± 12 150± 13∗ 149± 18 142± 18 −7.8± 9.9 150± 19 142± 18 −7.8± 7.6
Visceral fat (cm2)† 32± 2 46± 3∗ 43± 4 42± 5 −1.3± 3.6 49± 5 33± 2b −16± 5.4e
Hepatic fat (%)† 12.6± 1.4 16.7± 1.0∗ 17.0± 1.4 19.8± 1.4i 2.8± 1.4 16.5± 1.4 10.1± 0.9c −6.4± 1.0g
Values aremean ± SEM. BMI: bodymass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; CRP: c-reactive protein; N/L: neutrophile-to-lymphocyte
ratio; HOMA-IR: homeostatic model assessment-insulin resistance; HMW: adiponectin, high molecular weight; TC: total cholesterol; TG, triglycerides; SHBG: sex
hormone binding globulin; D4-A: 4-androstenedione; DHEAS: dehydroisoandrosterone sulphate. †By MRI; ∗p < 0 05, ∗∗p < 0 01, and ∗∗∗p < 0 001 between
controls and PCOS girls at baseline. aNo significant differences between randomized PCOS subgroups at baseline; bp < 0 05, cp < 0 01, and dp < 0 001 within
subgroups for 0-to-12-month changes (Δ); ep < 0 05, fp < 0 01, and gp < 0 001 between subgroups for 0-to-12-month changes (Δ); hp < 0 01 and ip < 0 001



















Figure 1: Longitudinal fetuin-A concentrations (mean± SEM) in adolescent girls with polycystic ovary syndrome who were randomized to
receive either an oral contraceptive [ethinylestradiol-levonorgestrel (EE-LNG) n = 18] or low-dose spironolactone (50mg/d), pioglitazone
(7.5mg/d) plus metformin (850mg/d) (SPIOMET, n = 17), for 12 months. Control girls (n = 25) matched for age and body mass index
were assessed for comparison. ∗∗∗P < 0 001 for baseline differences between patients and controls; ∗∗P < 0 01 within patient subgroups for
0 to 12 months and between groups at 12 months.
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4. Discussion
Here, we characterize for the first time the longitudinal out-
come of circulating fetuin-A concentrations in nonobese
adolescents with PCOS and show that fetuin-A levels nor-
malize after treatment with a low-dose combination of insu-
lin sensitizers and an antiandrogen, but not after OC.
Growing evidence supports the relationship between
fetuin-A and hepatic fat depots in obesity [11]. Also, strong
associations between fetuin-A and insulin resistance have
been reported in subjects without diabetes [12]; indeed,
fetuin-A promotes insulin resistance through inhibition of
insulin receptor tyrosine kinase in hepatocytes and skeletal
muscle and activation of Toll-like receptor 4 in response
to free fatty acids, stimulating an inflammatory signaling
pathway [2, 13]. In contrast, other studies report no associ-
ations between fetuin-A and insulin resistance in T2D
patients or suggest that fetuin-A is not causally related to
diabetes risk [14, 15]. Moreover, the impact of fetuin-A
on cardiovascular disease is controversial depending on
the presence or absence of diabetes. For example, nondia-
betic subjects—but not T2D patients—with higher fetuin-
A levels have a lesser risk for cardiovascular disease and
related mortality [14]. Besides, fetuin-A would prevent liver
and vascular fibrosis through the inhibition of transforming
growth factor-β1 signaling [16].
Our apparently discordant data could be partially
explained bearing in mind that fetuin-A comprises a mix-
ture of circulating isoforms regulating specific biological
processes and that the available ELISA assays may differ
in their specificity for different glycosylated forms [17].
Moreover, defects of glycosylation/sialylation of fetuin-A
leading to protein inactivation have also been reported, indi-
cating that the overall glycosylation status of fetuin-A would
also be relevant in the regulation of fetuin-A actions [18].
Fetuin-A also has an anti-inflammatory role, acting as
endogenous inhibitor of zinc metalloproteases [19]. This fea-
ture could explain the association between fetuin-A concen-
trations and the change in CRP levels over 12 months in
the girls receiving SPIOMET, suggesting that fetuin-A levels
within the normal range are required to maintain inflamma-
tion homeostasis.
The dual functionality of fetuin-A in diabetes risk, inflam-
mation, and cardiovascular disease raises the question as to
whether decreasing fetuin-A concentrations should be cus-
tomarily recommended [20], especially taking into account
the heterogeneity of fetuin-A levels reported in different stud-
ies using the same method in similar age groups [21].
The finding of lower levels of fetuin-A in PCOS girls was
unexpected and could be derived—at least in part—from the
status of low-grade inflammation associated with this
entity, since it is known that proinflammatory cytokines
and proteins such as CRP—which are increased in
PCOS—downregulate fetuin-A expression in the liver [4, 22].
This would also explain the negative association between
fetuin-A concentrations and hepatic fat. SPIOMET treat-
ment was followed by a healthier endocrine-metabolic pro-
file, as judged by the reduction of insulin levels and the drop
in ectopic fat; in addition, SPIOMET but not OC raised
fetuin-A levels towards normal. This finding may be per-
ceived as contradictory, because pioglitazone—but not met-
formin—has been reported to reduce fetuin-A levels in
patients with T2D [23]. However, in those studies, pioglita-
zone was given in monotherapy, and at doses, at least four-
fold higher [23].
The main study limitations include the small sample
size and the lack of obese PCOS and obese control girls, pre-
cluding to discern the separate effects of obesity and PCOS
on fetuin-A levels. The strengths include the longitudinal
design, the homogeneous study population, and the assess-
ment of the impact of two interventions with divergent
effects on the endocrine-metabolic status and, potentially,
on cardiometabolic risk. The cross-sectional nature and
population heterogeneity of the so far available studies in
PCOS women may explain the discrepancies among popu-
lations [7–9].
5. Conclusions
In conclusion, we report for the first time that fetuin-A levels
are reduced in nonobese girls with PCOS and that a low-dose
combination of insulin sensitizers and an antiandrogen—but
not an OC—increases towards normal fetuin-A concentra-
tions, together with an improvement of the endocrine-
metabolic status. The divergent regulation and thus potential
duality of fetuin-A effects in diverse pathological conditions
deserve further investigation.
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